Patents Assigned to Eli Lilly and Company
  • Patent number: 10654866
    Abstract: Novel selective estrogen receptor degraders (SERDs) according to the formula: pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, wherein either R1 or R2 is independently selected from Cl, F, —CF3, or —CH3, and the other is hydrogen, and methods for their use are provided.
    Type: Grant
    Filed: July 11, 2019
    Date of Patent: May 19, 2020
    Assignee: Eli Lilly and Company
    Inventors: Jolie Anne Bastian, Jeffrey Daniel Cohen, Almudena Rubio, Daniel Jon Sall
  • Patent number: 10647759
    Abstract: Antibodies to human N3pGlu A?, compositions comprising such N3pGlu A? antibodies, and methods of using such N3pGlu A? antibodies for the treatment of a disease characterized by deposition of A? including clinical or pre-clinical Alzheimer's disease, Down's syndrome, and clinical or pre-clinical cerebral amyloid angiopathy.
    Type: Grant
    Filed: April 16, 2018
    Date of Patent: May 12, 2020
    Assignee: Eli Lilly and Company
    Inventors: Ronald Bradley Demattos, Jirong Lu, Ying Tang
  • Publication number: 20200123154
    Abstract: The present invention provides a compound of Formula (I), wherein X is H or C1-C3 alkyl optionally substituted with hydroxyl; Y is H, hydroxy, or methyl; R is ethyl, n-propyl, cyclopropyl, or Formula (II); and A is methyl, cyclopropyl or trifluoromethyl; or a pharmaceutically acceptable salt thereof; with the proviso that when X and Y are both H and R is n-propyl, then A is other than methyl; for use as a human PDE1 inhibitor.
    Type: Application
    Filed: July 26, 2018
    Publication date: April 23, 2020
    Applicant: Eli Lilly and Company
    Inventors: Michael James Genin, William Glen Holloway, Richard Duane Johnston, John Richard Morphy, Qing Shi
  • Publication number: 20200121685
    Abstract: Methods of treating Primary Biliary Cholangitis and/or Primary Sclerosing Cholangitis with baricitinib, including formulations and dose regimens. The amount of baricitinib may be administered as a 4 mg tablet or pill that includes one or more excipients. The amount of baricitinib may be administered daily or at some other frequency.
    Type: Application
    Filed: October 10, 2019
    Publication date: April 23, 2020
    Applicant: Eli Lilly and Company
    Inventors: Patrick L. McCollam, James Michael McGill, Ana Luisa de Macedo Pinto Correia
  • Patent number: 10627377
    Abstract: A centrifugation approach used to accelerate current empirical methods used to investigate silicone drainage in syringes is disclosed. A siliconized syringe is placed into a holder of a centrifuge in a predefined orientation. Centrifugation of the syringe is activated at a predetermined G rate and for a period of intended simulation time and is ended as that time elapses. The time can be a function of intended simulation time, acceleration due to gravity, square of centrifuge revolution rate, and distance from center of rotor hub to matching point on the syringe barrel. One or more injection functionality parameters of the syringe is assessed after the elapsed period of time. A bucket fixture for retaining one or more syringes in the predefined orientation is also disclosed.
    Type: Grant
    Filed: October 11, 2018
    Date of Patent: April 21, 2020
    Assignee: Eli Lilly and Company
    Inventors: Brian Frank Lewis, Bernard Michael McGarvey
  • Patent number: 10618974
    Abstract: Antibodies to tropomysin receptor kinase (TrkA), compositions including such antibodies, and methods of using such antibodies for the treatment of pain including post-surgical pain, rheumatoid arthritis pain, neuropathic pain and osteoarthritis pain.
    Type: Grant
    Filed: February 21, 2019
    Date of Patent: April 14, 2020
    Assignee: Eli Lilly and Company
    Inventors: Catherine Brautigam Beidler, Daniel Scott Girard, Chetankumar Natvarlal Patel
  • Patent number: 10611751
    Abstract: The invention provides certain (phenyl)-(pyrazol)-3,4-dihydroisoquinolin-2(1H)-yl)ethan-1-one compounds of formula I as D1 positive allosteric modulators (PAMs), and pharmaceutical compositions thereof. The invention further provides methods of using a compound of formula I, or a pharmaceutically acceptable salt thereof, to treat certain symptoms of Parkinson's disease, schizophrenia, ADHD or Alzheimer's disease.
    Type: Grant
    Filed: April 17, 2019
    Date of Patent: April 7, 2020
    Assignee: Eli Lilly and Company
    Inventors: Darryl Wayne Hilliard, Junliang Hao, David Andrew Coates
  • Patent number: 10604573
    Abstract: Antibodies which bind BTLA, and methods of using same, are provided, said antibodies are useful as agents for treating conditions associated with autoimmune disease including treating lupus.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: March 31, 2020
    Assignee: Eli Lilly and Company
    Inventors: Shane Krummen Atwell, Andrew Charles Vendel, Victor H. Obungu
  • Patent number: 10603320
    Abstract: The present invention provides novel ROR gamma-t inhibitors and pharmaceutical compositions thereof. Formula (I).
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: March 31, 2020
    Assignee: Eli Lilly and Company
    Inventors: Charles Willis Lugar, III, John Richard Morphy, Timothy Ivo Richardson, Helene Catherine Eugenie Rudyk, Selma Sapmaz, Ryan Edward Stites
  • Patent number: 10597436
    Abstract: The presently described compounds relate to the treatment of diabetes and/or hyperglycemia. More particularly, the described compounds relate to acylated insulin compounds that lower blood glucose, pharmaceutical compositions containing such compounds, therapeutic uses of such compounds, and an intermediate compound used to make the acylated insulin compounds.
    Type: Grant
    Filed: August 1, 2019
    Date of Patent: March 24, 2020
    Assignee: Eli Lilly and Company
    Inventors: Wen Liu, Adam Robert Mezo, Francisco Alcides Valenzuela
  • Patent number: 10584174
    Abstract: Bispecific antibody compounds, and methods of using same, are provided which bind and neutralize Dkk-1 and RANKL and which are useful as adjuncts to spinal fusion surgery or as agents for bone healing or treating conditions associated with bone loss or degeneration.
    Type: Grant
    Filed: May 12, 2016
    Date of Patent: March 10, 2020
    Assignee: Eli Lilly and Company
    Inventors: Victor H Obungu, Andrew Korytko
  • Patent number: 10577415
    Abstract: IgG bispecific antibodies are provided that bind human Calcitonin Gene Related Peptide (CGRP) and human Interleukin-23 (IL-23) and are characterized as having high affinity and strong simultaneous neutralizing properties to both human CGRP and human IL-23. The bispecific antibodies of the invention are useful for treating various autoimmune diseases including Inflammatory Bowel Disease, such as Crohn's Disease (CD) and Ulcerative Colitis (UC), and other autoimmune diseases such as psoriatic Arthritis (PsA), ankylosing spondylitis (AS) and atopic dermatitis (AtD). The bispecific antibodies of the invention are useful for treating pain associated with the aforementioned diseases.
    Type: Grant
    Filed: April 26, 2018
    Date of Patent: March 3, 2020
    Assignee: Eli Lilly and Company
    Inventors: Robert Jan Benschop, Stephen John Demarest, Xiufeng Wu
  • Publication number: 20200062836
    Abstract: The invention provides for methods, treatments, and uses for anti-human VEGFR-2 antibodies for the treatment of metastatic colorectal cancer in patients having elevated levels of VEGF-D.
    Type: Application
    Filed: November 10, 2017
    Publication date: February 27, 2020
    Applicant: Eli Lilly and Company
    Inventors: Rebecca Rose HOZAK, Tara Suzanne UMBERGER
  • Patent number: 10562982
    Abstract: The present invention provides methods for producing Fabs and bi-specific antibodies comprising designed residues in the interfaces of the heavy chain-light chain variable (VH/VL) domain and the heavy chain-light chain constant (CH1/CL) domain, Fabs and bi-specific antibodies produced according to said processes and host cells encoding the same.
    Type: Grant
    Filed: March 11, 2019
    Date of Patent: February 18, 2020
    Assignees: Eli Lilly and Company, The University of North Carolina at Chapel Hill
    Inventors: Stephen J Demarest, Xiufeng Wu, Raheleh Toughiri, Brian Arthur Kuhlman, Steven Morgan Lewis
  • Patent number: 10555951
    Abstract: A method and medicament comprising 4,4,4-trifluoro-N-[(1S)-2-[[(7S)-5-(2-hydroxyethyl)-6-oxo-7H-pyrido[2,3-d][3]benzazepin-7-yl]amino]-1-methyl-2-oxo-ethyl]butanamide or a pharmaceutically acceptable salt or hydrate thereof for treating leiomyosarcoma is provided.
    Type: Grant
    Filed: April 6, 2016
    Date of Patent: February 11, 2020
    Assignee: ELI LILLY AND COMPANY
    Inventors: Karim A. Benhadji, Christophe Massard, Jean-Charles Soria
  • Patent number: 10555944
    Abstract: Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X1, X2, X3, X4, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
    Type: Grant
    Filed: October 29, 2018
    Date of Patent: February 11, 2020
    Assignee: Eli Lilly and Company
    Inventors: Steven W. Andrews, Sean Aronow, James F. Blake, Barbara J. Brandhuber, Adam Cook, Julia Haas, Yutong Jiang, Gabrielle R. Kolakowski, Elizabeth A. McFaddin, Megan L. McKenney, Oren T. McNulty, Andrew T. Metcalf, David A. Moreno, Tony P. Tang, Li Ren
  • Patent number: 10537676
    Abstract: A fluid sensing system (30) including a fluid channel (32) with an inlet (34) and an outlet (36). A thermal device (38) is operably coupled thereto at a first position whereby thermal energy is transferable with fluid in the channel. A section of the fluid channel downstream of the first position has a predefined cross section and flow path. A thermal imaging device (46) is positioned to capture a thermal image of at least a portion of the downstream section. A processor (48) coupled with the thermal imaging device is configured to determine at least one output value representative of a property of the fluid medication or fluid flow using the thermal image. The output value may be the flow volume. In some embodiments, the fluid channel also defines a section upstream of the first position with the thermal imaging device capturing an image that includes at least portions of both the upstream and downstream sections.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: January 21, 2020
    Assignee: Eli Lilly and Company
    Inventors: Phillip W. Barth, Mateusz B. Bryning, Leslie A. Field
  • Patent number: 10519158
    Abstract: The present invention relates to pharmaceutical compounds of the Formula (I), or a pharmaceutically acceptable salt or composition thereof, and methods of their use for the treatment of pain, respiratory conditions, as well as inhibiting the Transient Receptor Potential A1 ion channel (TRPA1).
    Type: Grant
    Filed: December 28, 2018
    Date of Patent: December 31, 2019
    Assignee: Eli Lilly and Company
    Inventors: Bertrand L. Chenard, Xinyuan Wu
  • Patent number: 10519225
    Abstract: Antibodies to human pituitary adenylate cyclase-activating peptide, compositions comprising such antibodies, and methods of using such antibodies for the treatment of pain including headache and/or migraine.
    Type: Grant
    Filed: September 20, 2018
    Date of Patent: December 31, 2019
    Assignee: Eli Lilly and Company
    Inventors: Chetankumar Natvarlal Patel, Michael Parvin Johnson, Catherine Brautigam Beidler
  • Patent number: D881004
    Type: Grant
    Filed: July 11, 2019
    Date of Patent: April 14, 2020
    Assignee: Eli Lilly and Company
    Inventors: Jean-Pierre Giraud, Brian Fitzpatrick, Brian Tifft, Andrew Snow, Jaime Arnett